GSK plans 121 job cuts at Irish plant; Novartis wins suit over Zometa;

 @FiercePharma: Pharma cuts 6,000+ jobs in Sept. Article | Follow @FiercePharma

> GlaxoSmithKline has completed its review of a manufacturing facility in Ireland and concluded that it will have to shed 121 staff from its 450-plus workforce. Report

> A New Jersey jury ruled that Novartis provided adequate warnings about the risk of its bone-strengthening medicines, rejecting a lawsuit by a woman who claimed the drugs destroyed her jaw. Report

> New details are emerging about shortcomings at Gilead Sciences' San Dimas, California, plant as the FDA posted its warning letter about those problems. Report

> U.S. health regulators plan to spend millions of dollars to step up their scientific prowess in a move that officials say will help quickly get new treatments to patients and protect the public against possible health threats. Report

> GeneScience Pharmaceutical, a Chinese drug company, and its chief executive have agreed to plead guilty today to charges of illegally distributing human growth hormones in the U.S. Report

> Swedish contract development and manufacturing services company Recipharm has agreed to buy a facility in Parets del Valles, Spain, from Abbott Laboratories for an undisclosed sum. Report

> With last week's announcement by the FDA that it was ordering unapproved colchicine products off the market, the year-old debate over the agency's handling of the popular gout treatment has flared anew. Report

>GlaxoSmithKline has retained an 18 percent minority equity stake in spin-off biotechnology group Convergence Pharmaceuticals, which was officially launched yesterday with financing of $35.4 million from a syndicate of leading European and U.S. life science investors. Report

Biotech News

 @FierceBiotech: Investors buck as Crucell backs J&J's $2.4B bid. Article | Follow @FierceBiotech

 @JohnCFierce: Biogen Idec's new chief is planning a big revamp of R&D, with more collaborations involving small biotechs. Article |  Follow @JohnCFierce

> Novartis, Venter team on faster vax development. Report

> Pirfenidone will make or break InterMune. Article

> With $1.25B bond sale, Celgene eyes deals. Story

> Targacept ADHD candidate shows disappointing results in Ph2 trial. Item

Manufacturing News

> RFID system targets drug fakes in Nigeria. Report

> Caraco leads ops-margin minimizers. News

> Faulty sieve likely shed metal, driving pill recall. Article

> For J&J, Crucell ops quality an acquisition bonus. Story

> Gilead warning cites animated operator. News

Vaccines News

> Celldex vax extends life of brain tumor patients in study. Story

> Offit: Children's vaccines are vital. Report

> Combo anthrax/smallpox vax beats anthrax vax alone. Article

And Finally... A strain of a drug-resistant skin disease that has afflicted sports teams, prisons and military units is now proving a persistent pest among lobstermen and their families on a Maine island. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.